B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIN2C

MOLECULAR TARGET

glutamate ionotropic receptor NMDA type subunit 2C

UniProt: Q14957NCBI Gene: 290516 compounds

GRIN2C (glutamate ionotropic receptor NMDA type subunit 2C) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIN2C

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Glutamic Acid3.2224
2Glutamic Acid3.2224
3Glycine2.4010
4Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of1.795
5Levorphanol1.795
6pentamidine1.795
7Aspartic Acid1.393
8cycloserine1.393
9D-Aspartic Acid1.102
10Dextrorphan Dextro form of levorphanol. It acts as1.102
11Ethidium1.102
12Dextrothyroxine0.691
13Dizocilpine Maleate0.691
14eliprodil0.691
15Ibotenic Acid0.691
16Spermine0.691

About GRIN2C as a Drug Target

GRIN2C (glutamate ionotropic receptor NMDA type subunit 2C) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented GRIN2C interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIN2C inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.